Medication info
TripM Duo Tablet 2.5/1000 mg (Linagliptin, Metformin)

TripM Duo Tablet 2.5/1000 mg (Linagliptin, Metformin)

Prescription medicationTabletOral
Ingredient · strength
Linagliptin Besylate›3.34mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Mothers Pharmaceutical Co., Ltd.
Appearance
Pink, bilaterally convex, oval film-coated tablet
Packaging
30 tablets/bottle, 60 tablets/bottle
Approval status
Active

MFDS item code 202401057 · Approved 2024.04.30

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dosage of this medication should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 2.5 mg (linagliptin besylate 3.34mg) and metformin 1000 mg twice daily. This medication should be administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dosage should be increased gradually. 1. Patients not currently receiving metformin: For patients who have not previously received antidiabetic drug therapy and whose blood glucose cannot be adequately controlled with monotherapy, the initial dosage is 1 tablet of this medication 2.5/500 mg twice daily. The dosage may be increased to 1 tablet of this medication 2.5/1000 mg twice daily. 2. Patients who cannot achieve adequate glycemic control with metformin monotherapy: The initial dosage of this medication should be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medication should start with their current doses of linagliptin and metformin. 4. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea: The initial dosage of this medication should be considered to be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medication is coadministered with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Use with Caution in the Following Patients). 5. Patients who cannot achieve adequate glycemic control with combination therapy of insulin and metformin: The initial dosage of this medication should be considered to be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medication is coadministered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Use with Caution in the Following Patients). No studies have been conducted to evaluate the safety and efficacy of switching to this medication in patients previously treated with other oral antihyperglycemic agents. Any change in the treatment regimen for type 2 diabetes mellitus may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medication may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2) who have no other symptoms that may increase the risk of lactic acidosis, with the following dosage adjustment. Treatment should not be initiated with this medication because the starting dose of metformin is 500mg or 850mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medication should be discontinued immediately. Patients with hepatic impairment This medication should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).

Ingredients

Manufacturer
Mothers Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication is used as an adjunct to diet and exercise to assist patients with Type 2 diabetes who need to use linagliptin and metformin together in managing their blood glucose levels. It helps to effectively control blood glucose levels and has a positive impact on the patient's diabetes management.

How to take

Adult dose

The dosage of this medication should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 2.5 mg (linagliptin besylate 3.34mg) and metformin 1000 mg twice daily. This medication should be administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dosage should be increased gradually. 1. Patients not currently receiving metformin: For patients who have not previously received antidiabetic drug therapy and whose blood glucose cannot be adequately controlled with monotherapy, the initial dosage is 1 tablet of this medication 2.5/500 mg twice daily. The dosage may be increased to 1 tablet of this medication 2.5/1000 mg twice daily. 2. Patients who cannot achieve adequate glycemic control with metformin monotherapy: The initial dosage of this medication should be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medication should start with their current doses of linagliptin and metformin. 4. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea: The initial dosage of this medication should be considered to be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medication is coadministered with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Use with Caution in the Following Patients). 5. Patients who cannot achieve adequate glycemic control with combination therapy of insulin and metformin: The initial dosage of this medication should be considered to be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medication is coadministered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Use with Caution in the Following Patients). No studies have been conducted to evaluate the safety and efficacy of switching to this medication in patients previously treated with other oral antihyperglycemic agents. Any change in the treatment regimen for type 2 diabetes mellitus may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medication may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2) who have no other symptoms that may increase the risk of lactic acidosis, with the following dosage adjustment. Treatment should not be initiated with this medication because the starting dose of metformin is 500mg or 850mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medication should be discontinued immediately. Patients with hepatic impairment This medication should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).

Precautions

This medication is used to control blood glucose levels. While taking this medication, there is a rare but serious side effect known as lactic acidosis, and therefore it should not be administered to patients with impaired kidney function or with problems related to the heart or liver. Additionally, this medication should not be used in pregnant or breastfeeding women, nor in situations such as acute infections or severe trauma that can quickly worsen kidney function. Due to the risk of hypoglycemia, careful monitoring of blood glucose changes is necessary when used in conjunction with insulin or sulfonylureas, and dosage adjustments of other medications may be required as needed. Elderly patients with decreased kidney function or certain conditions should regularly have kidney function tests, and the dosage may need to be adjusted based on their condition. If symptoms of acute pancreatitis or skin blisters such as vesicular pemphigoid appear, the medication should be immediately discontinued, and a doctor should be consulted. Avoid alcohol consumption during treatment, and consult with healthcare professionals as there may be interactions when taking other medications together. Safety and efficacy in children under 10 years have not been established, and its use is not recommended in this age group. The use of this medication should be temporarily halted before and after tests that can affect kidney function, such as surgery or radiological examinations. This medication may cause side effects such as gastrointestinal disturbances, fatigue, headaches, and dizziness, and if symptoms are severe or persistent, the doctor should be informed. Finally, this medication should be stored out of reach of children, kept away from moisture, and not transferred to another container.

Side effects

  • Lactic acidosis
  • nasopharyngitis
  • hypersensitivity
  • angioedema
  • urticaria
  • decreased and deficiency of vitamin B12
  • hypoglycemia
  • taste disturbance
  • cough
  • decreased appetite
Show 128 more
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
  • abdominal pain
  • formation of oral ulcers
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • blistering dermatitis herpetiformis
  • severe and disabling arthralgia
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • constipation
  • upper abdominal pain
  • enterocolitis
  • bowel obstruction
  • gastroenteritis
  • herpes zoster
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • decreased appetite
  • dehydration
  • hyperglycemia
  • cerebral infarction
  • speech disturbance
  • Alzheimer's dementia
  • chest pain
  • fever
  • facial swelling
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot
  • skin lesions
  • liver metastasis
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • rectal cancer
  • pancreatic cancer
  • meniscal injury
  • pneumoconiosis
  • congestive heart failure
  • angina pectoris
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage renal disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • dizziness
  • kidney transplant failure
  • pneumonia
  • hypertension
  • itching
  • insomnia
  • depression
  • angina pectoris
  • acute myocardial infarction
  • unstable angina
  • diarrhea
  • pancreatitis
  • stomatitis
  • mediastinitis
  • vitreous hemorrhage
  • fever
  • ligament sprain
  • flank pain
  • myelodysplastic syndrome
  • vocal fold polyp
  • gingivitis
  • dyspepsia
  • upper abdominal pain
  • stomatitis
  • dizziness
  • chest pain
  • shortness of breath
  • osteoarthritis
  • limb pain
  • increased blood creatinine
  • male-pattern baldness
  • diabetic foot
  • hyperhidrosis
  • alopecia
  • dermatitis
  • anxiety
  • affective disorder
  • contusion
  • bone contusion
  • concussion
  • bone fracture
  • hand fracture
  • laceration
  • palpitations
  • dry eye
  • cataract
  • eye discomfort
  • allergic conjunctivitis
  • polyuria
  • proteinuria
  • stress urinary incontinence
  • hematuria
  • hypotension
  • flushing
  • fatty liver
  • cholelithiasis
  • hearing loss
  • erectile dysfunction
  • goiter
  • anemia
  • delirium
  • nocturia
  • dermatitis
  • hypertension

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and moisture. It is recommended to store it at room temperature, between 1 to 30 degrees Celsius, avoiding extremes in temperature.

Appearance and packaging

Appearance

Pink, bilaterally convex, oval film-coated tablet

Package unit

30 tablets/bottle, 60 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.